Sucralfate is one of those “quiet” GI drugs that doesn’t show up on wards as often as PPIs—but it loves showing up on Step questions because its mechanism is distinct, its adverse effects are very testable, and it ties neatly into ulcer pathophysiology. If you can picture what it’s physically doing in the stomach (and what it needs to work), you’ll get almost every sucralfate question right.
Where Sucralfate Fits in GI Pharmacology (Big Picture)
Peptic ulcer disease (PUD) and erosive mucosal disease result from an imbalance between:
- Aggressive factors: gastric acid, pepsin, H. pylori, NSAIDs (↓ prostaglandins)
- Defensive factors: mucus/bicarbonate layer, mucosal blood flow, epithelial restitution, prostaglandins
Most anti-ulcer drugs either:
- Decrease acid (PPIs, H2 blockers), or
- Increase mucosal protection (sucralfate, bismuth, misoprostol)
Sucralfate is primarily a mucosal protectant. It doesn’t neutralize acid and doesn’t suppress acid secretion—it shields damaged mucosa.
Definition (What It Is)
Sucralfate is a sulfated polysaccharide (a sucrose polymer) complexed with aluminum hydroxide.
Core concept: it forms a protective barrier over ulcers/erosions.
Mechanism of Action (The Step 1 Version You Must Know)
The key requirement: an acidic environment
In the low pH of the stomach, sucralfate polymerizes and becomes a sticky, viscous paste that binds to proteins in the ulcer base (e.g., exposed collagen).
What it does
- Coats ulcers → creates a physical barrier against:
- acid
- pepsin
- bile salts
- Also stimulates local protective factors (high-yield but secondary):
- ↑ prostaglandins
- ↑ bicarbonate secretion
- ↑ mucus production
What it does not do
- Does not meaningfully raise gastric pH
- Does not inhibit acid secretion directly
High-yield one-liner:
Sucralfate forms a protective barrier over ulcers and requires an acidic environment to work.
Pathophysiology Connections (Why This Makes Sense)
Sucralfate is most useful when the problem is mucosal injury and you want to:
- protect the ulcer base, and
- allow re-epithelialization to occur
This is why sucralfate shows up in association with:
- stress-related mucosal disease (less common now vs PPIs/H2 blockers in ICUs)
- duodenal ulcers (classic board association; still used selectively)
- situations where systemic effects are undesirable, since it’s minimally absorbed
Clinical Presentation: When Might You See It Used?
Sucralfate may be used in patients with:
- Peptic ulcer disease symptoms
- epigastric pain
- postprandial timing depends on gastric vs duodenal ulcer patterns
- GERD/esophagitis (sometimes used, though PPIs are first-line)
- Stress ulcer prophylaxis (historically; now more often PPIs/H2 blockers)
Test-taking pearl: If the stem emphasizes a drug that “coats” ulcers or “adheres to” the ulcer base—think sucralfate.
Diagnosis: Not a “Sucralfate Diagnosis,” But Know the Ulcer Workup
Sucralfate doesn’t diagnose anything; it treats mucosal injury. Boards may still embed it in a PUD scenario:
Peptic ulcer disease evaluation (Step-level)
- Alarm symptoms → endoscopy (EGD)
- weight loss, anemia, GI bleeding, dysphagia, persistent vomiting, older age with new symptoms
- Suspected H. pylori:
- urea breath test
- stool antigen test
- biopsy urease test (during EGD)
Important: If the patient has H. pylori, eradication therapy is the definitive management—sucralfate is not a substitute for triple/quadruple therapy.
Treatment: How Sucralfate Is Used (and How Step Tests It)
Typical role
- Adjunct or alternative therapy for ulcer healing and mucosal protection
- Not first-line for most PUD in modern practice (PPIs dominate), but Step questions love its unique MOA and side effects
Administration pearls (high yield)
Because sucralfate binds things, timing matters:
- Best taken on an empty stomach
- Can impair absorption of many medications by binding them in the GI tract
→ often separate administration by at least ~2 hours (test concept > exact number)
Interaction with acid suppression (very testable)
Sucralfate needs acid to polymerize. If gastric pH is increased, it may work less effectively.
- Antacids, H2 blockers, PPIs can reduce its activation if taken simultaneously
→ separate dosing if used together
Adverse Effects (Where Many Questions Live)
1) Constipation
- Due to the aluminum component
Classic Step association: “ulcer drug” + constipation → sucralfate
2) Aluminum toxicity risk in renal failure
Sucralfate is minimally absorbed, but aluminum exposure matters more in:
- chronic kidney disease (CKD) / renal failure
- risk of aluminum accumulation (think neurotoxicity, bone disease—rare, but board-relevant as a concept)
3) Drug-binding interactions
By forming a barrier and binding proteins/meds, it can decrease absorption of:
- some antibiotics (commonly tested conceptually; tetracyclines/fluoroquinolones are classic “chelation/binding” culprits in pharm generally)
- other oral meds with narrow therapeutic windows (concept: separate dosing)
Contraindications / Cautions (Quick Hits)
- Renal failure: caution due to aluminum accumulation
- Patients with significant polypharmacy: consider interaction risk (binding/absorption issues)
HY Step 1 Associations (Rapid Review)
If you remember nothing else
- MOA: Coats ulcers; forms protective barrier
- Requires acidic environment
- Adverse effect: constipation
- Contains aluminum → caution in renal failure
- Decreases absorption of other drugs → separate dosing
Sucralfate vs Other Ulcer Drugs (High-Yield Comparison Table)
| Drug/Class | Primary action | Key “tell” on exams | Notable adverse effects |
|---|---|---|---|
| Sucralfate | Coats ulcer base; mucosal protection | Barrier + needs acid | Constipation, ↓ drug absorption, aluminum issues in CKD |
| PPIs (e.g., omeprazole) | Irreversibly inhibit H⁺/K⁺ ATPase | Most potent acid suppression | C. diff, pneumonia, hypomagnesemia, fractures (classic associations) |
| H2 blockers (e.g., famotidine) | Block H2 receptors on parietal cells | “Less potent than PPIs” | Cimetidine: gynecomastia, CYP inhibition, confusion |
| Misoprostol | PGE₁ analog → ↑ mucus/bicarb, ↓ acid | Prevents NSAID ulcers | Diarrhea, uterine contraction (contraindicated in pregnancy) |
| Bismuth | Coats ulcers + antimicrobial effect vs H. pylori | Part of quadruple therapy | Black stools/tongue |
First Aid Cross-References (How It’s Usually Listed)
In First Aid (GI Pharmacology—Acid Suppression & Ulcer Therapy), sucralfate is typically grouped with mucosal protective agents alongside bismuth and misoprostol.
First Aid-style bullets to mirror:
- Sucralfate: protective barrier, requires acidic environment
- Adverse effects: constipation
- Drug interactions: ↓ absorption of other drugs
(Page numbers vary by edition—use the GI Pharmacology section under peptic ulcer therapy/acid suppression.)
Board-Style Mini Prompts (Self-Check)
-
A patient with a duodenal ulcer is started on a drug that forms a viscous paste in the stomach and adheres to the ulcer base.
- What is it? Sucralfate
- Needs what to activate? Acidic pH
-
Same patient returns with constipation after starting ulcer therapy.
- Which agent is most likely? Sucralfate
-
CKD patient needs ulcer protection; which drug warrants caution due to aluminum accumulation?
- Sucralfate
Takeaway
Sucralfate is a mucosal protectant that physically coats ulcers and requires an acidic environment to do so. Step questions disproportionately test its constipation, aluminum/renal failure caution, and drug-binding interactions. If you can visualize it as “ulcer bandage paste,” you’ll recognize it instantly.